|
|
# 2024 AmCURE Antibiotic |
|
Antimicrobial resistance (AMR) poses a grave risk, potentially ushering in a “post-antibiotic era” where even minor infections could become deadly. Traditional antibiotics are losing efficacy, and new alternatives, like cationic polymers, show promise but face issues with in vivo toxicity. AmCURE addresses this by employing a “caging” strategy, where antimicrobials are deactivated and safely contained until reaching the infection site. This method releases the antimicrobials only in the presence of specific bacterial enzymes, reducing toxicity and enhancing treatment efficacy
Bo Zhang is a final-year Ph.D. candidate in Chemical and Biomedical Engineering at Nanyang Technological University, Singapore. He received his B.Sc. in Pharmaceutical Sciences in 2021 from Peking University, China, after which he came to NTU to pursue a doctoral degree with a research focus on novel antimicrobials to combat the emerging global antibiotic resistance crisis. Bo also has experience developing commercialization plans for the medical diagnostic technology developed by his lab and has interned for a biopharmaceutical private equity firm. Upon completion of Ph.D., he intends to dedicate himself to the commercialization and clinical translation of innovative medicine. more
Universidad de Ingeniería y Tecnología – UTEC
Decellularized ECM model for breast cancer studies
